4893 items matching your search terms.

Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease

Fonarow, G. C. Keech, A. C. Pedersen, T. R. Giugliano, R. P. Sever, P. S. Lindgren, P. van Hout, B. Villa, G. Qian, Y. Somaratne, R. Sabatine, M. S.
JAMA CARDIOL, 2017     DOI:10.1001/jamacardio.2017.2762

Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice

Foote, C. Woodward, M. Jardine, M. J.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2017     DOI:10.1053/j.ajkd.2017.02.005

Health-related quality of life and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 phase III trial

Friedlander, M. Gebski, V. Gibbs, E. Bloomfield, R. Hilpert, F. Wenzel, L.B. Joly, F. Eek, D. Rodrigues, M. Clamp, A.R. Penson, R.T. Provencher, D.M. Korach, J. Huzarski, T. Vidal, L. Salutari, V. Scott, C.L. Nicoletto, M.O. Tamura, K. Pujade-Lauraine, E.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy

Friedlander, M. Rau, J. Lee, C. K. Meier, W. Lesoin, A. Kim, J. W. Poveda, A. Buck, M. Scambia, G. Shimada, M. Hilpert, F. King, M. T. Debruyne, P. Bologna, A. Malander, S. Monk, B. J. Petru, E. Calvert, P. Herzog, T. J. Barrett, C. du Bois, A.
ANNALS OF ONCOLOGY, 2017     DOI:10.1093/annonc/mdx796

VESPRO: an individual patient data prospective meta-analysis of selective internal radiation therapy versus sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRveNIB trials

Gebski, V. Gibbs, E. Gandhi, M. Chatellier, G. Dinut, A. Pereira, H. Chow, P. K. Vilgrain, V.
JMIR RES PROTOC, 2017     DOI:10.2196/resprot.7016

Survival after laparoscopic vs abdominal hysterectomy-reply

Gebski, V. Janda, M. Obermair, A.
JAMA, 2017     DOI:10.1001/jama.2017.8165

A phosphorylatable sphingosine analog induces airway smooth muscle cytostasis and reverses airway hyperresponsiveness in experimental asthma

Gendron, D. R. Lecours, P. B. Lemay, A. M. Beaulieu, M. J. Huppe, C. A. Lee-Gosselin, A. Flamand, N. Don, A. S. Bissonnette, E. Blanchet, M. R. Laplante, M. Bourgoin, S. G. Bosse, Y. Marsolais, D.
FRONT PHARMACOL, 2017     DOI:10.3389/fphar.2017.00078

Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial

Giugliano, R. P. Keech, A. Murphy, S. A. Huber, K. Tokgozoglu, S. L. Lewis, B. S. Ferreira, J. Pineda, A. L. Somaratne, R. Sever, P. S. Pedersen, T. R. Sabatine, M. S.
JAMA CARDIOL, 2017     DOI:10.1001/jamacardio.2017.3944

Cognitive function in a randomized trial of evolocumab

Giugliano, R. P. Mach, F. Zavitz, K. Kurtz, C. Im, K. Kanevsky, E. Schneider, J. Wang, H. Keech, A. Pedersen, T. R. Sabatine, M. S. Sever, P. S. Robinson, J. G. Honarpour, N. Wasserman, S. M. Ott, B. R.
NEW ENGLAND JOURNAL OF MEDICINE, 2017     DOI:10.1056/NEJMoa1701131

Cognitive function in a randomized trial of evolocumab

Giugliano, R. P. Mach, F. Zavitz, K. Kurtz, C. Im, K. Kanevsky, E. Schneider, J. Wang, H. Keech, A. Pedersen, T. R. Sabatine, M. S. Sever, P. S. Robinson, J. G. Honarpour, N. Wasserman, S. M. Ott, B. R. Ebbinghaus Investigators
NEW ENGLAND JOURNAL OF MEDICINE, 2017     DOI:10.1056/NEJMoa1701131

Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therap: a cognitive study of patients enrolled in the FOURIER trial

Giugliano, R. P. Mach, F. Zavitz, K. Kurtz, C. Schneider, J. Wang, H. Keech, A. Pedersen, T. R. Sabatine, M. S. Sever, P. S. Honarpour, N. Wasserman, S. M. Ott, B. R. Ebbinghaus Investigators
CLINICAL CARDIOLOGY, 2017     DOI:10.1002/clc.22678

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy—A cognitive study of patients enrolled in the FOURIER trial

Giugliano, R. P. Mach, F. Zavitz, K. Kurtz, C. Schneider, J. Wang, H. Keech, A. Pedersen, T. R. Sabatine, M. S. Sever, P. S. Honarpour, N. Wasserman, S. M. Ott, B. R. on behalf of the, Ebbinghaus Investigators
CLINICAL CARDIOLOGY, 2017     DOI:10.1002/clc.22678

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Giugliano, R. P. Pedersen, T. R. Park, J. G. De Ferrari, G. M. Gaciong, Z. A. Ceska, R. Toth, K. Gouni-Berthold, I. Lopez-Miranda, J. Schiele, F. Mach, F. Ott, B. R. Kanevsky, E. Pineda, A. L. Somaratne, R. Wasserman, S. M. Keech, A. C. Sever, P. S. Sabatine, M. S. Fourier Investigators
LANCET, 2017     DOI:10.1016/S0140-6736(17)32290-0

Moving toward a unified platform for insulin delivery and sensing of inputs relevant to an artificial pancreas

Graf, A. McAuley, S. A. Sims, C. Ulloa, J. Jenkins, A. J. Voskanyan, G. O'Neal, D. N.
J DIABETES SCI TECHNOL, 2017     DOI:10.1177/1932296816682762

Overnight counter-regulatory hormone levels and next day glycemia in adults with type 1 diabetes during closed-loop insulin delivery versus sensor-augmented pump with low-glucose suspend

Graf, A. Ward, G. M. Vogrin, S. Sundararajan, V. Sharifi, A. De Bock, M. I. Jayawardene, D. Loh, M. M. Horsburgh, J. C. Berthold, C. L. Paramalingam, N. Bach, L. A. Colman, P. G. Davis, E. A. Grosman, B. Jenkins, A. J. Kumareswaran, K. Kurtz, N. Kyoong, A. MacIsaac, R. J. Roy, A. Jones, T. W. O'Neal, D. N.
DIABETES TECHNOLOGY AND THERAPEUTICS, 2017     DOI:10.1089/dia.2017.0049